Q-VANT Biosciences
Q-VANT Biosciences develops and manufactures sustainable saponin-based vaccine adjuvants (QS-21 INFINITY, QS-21 GH, QS-Oral, VAC Saponin) using its proprietary Q-SAP platform. It serves human and veterinary vaccine developers and global health programs, with SPI Pharma as exclusive global commercial partner.
- Company typePrivate
- Founded2022
- HeadquartersForestdale (Boston area), United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Q-VANT Biosciences does
Q-VANT Biosciences is a privately-held bioscience company founded in January 2022 and headquartered in Forestdale, Massachusetts, with manufacturing operations and an R&D center in Chile (Santiago and Los Angeles). The company develops and manufactures saponin-based vaccine adjuvants under its proprietary Q-SAP (Quillaja Sustainable Adjuvant Platform), which combines computational learning techniques with a multi-step purification process to extract and purify QS-21 and other saponin adjuvants from the full Quillaja biomass rather than just bark. According to the company, this approach increases production volumes by up to 1,000 times relative to traditional bark extraction, enabling billion-dose-scale annual output from sustainably sourced raw material. Q-VANT's product portfolio includes QS-21 INFINITY (high-purity human adjuvant), QS-21 GH (global health adjuvant), QS-Oral (oral/sublingual adjuvant), and VAC Saponin (veterinary adjuvant).
The company serves three primary customer segments: human vaccine developers and manufacturers, veterinary vaccine manufacturers, and global health organizations and governments. Its commercial model combines direct sales with an exclusive global channel partnership with SPI Pharma, signed in October 2023 alongside a corporate investment, which provides distribution, regulatory, and logistics infrastructure. Q-VANT also generates revenue through licensing and supply agreements and operates an open-access, IP-free model for global health applications. Strategic collaborations include Tulane University (supported by an NIH contract of up to $9.2 million and Gates Foundation funding of approximately $1.65 million for oral polio and diarrheal disease vaccines), PATH, In Vitro Plant-tech AB for plant-cell-culture biomass, and consortium memberships in RRPV and BioMap. Revenue figures are not publicly disclosed; the company's first commercial product, QS-21 GH, launched in June 2026.
Q-VANT Biosciences firmographics
Firmographics- Name
- Q-VANT Biosciences
- Legal name
- Q-Vant Biosciences, Inc.
- Website
- https://q-vant.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Q-VANT Biosciences develops and manufactures sustainable saponin-based vaccine adjuvants (QS-21 INFINITY, QS-21 GH, QS-Oral, VAC Saponin) using its proprietary Q-SAP platform. It serves human and veterinary vaccine developers and global health programs, with SPI Pharma as exclusive global commercial partner.
- Ownership category
- akta.pro rank
Q-VANT Biosciences industry classification
Industry- Product category
- Vaccine Adjuvants
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Vaccine Adjuvants & Formulation Systems (HLAIAEAI)
- akta.pro secondary industries
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Veterinary Vaccines (Biologics) (HLAMAEAL), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)
Keywords
Where Q-VANT Biosciences is headquartered
LocationHeadquarters
- HQ city
- Forestdale (Boston area)
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Q-VANT Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Saponin Adjuvant Product Sales: Q-VANT generates revenue through the sale of proprietary saponin-based adjuvants including QS-21 GH, QS-21 INFINITY, QS-Oral, and VAC Saponin to vaccine developers and manufacturers for use in human and animal vaccine formulations. Products are sold directly and through SPI Pharma as exclusive commercial channel partner.
- Licensing and Supply Agreements: Q-VANT provides open-access, IP-free access to its saponin adjuvants, enabling vaccine developers and manufacturers to incorporate adjuvants into next-generation vaccine programs. Revenue is generated through supply contracts and formulation support services.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Q-VANT Biosciences product offering
Product offeringCore offering
Q-VANT Biosciences manufactures and supplies saponin-based vaccine adjuvants — including QS-21 XP (INFINITY), QS-21 GH (Global Health), QS-Oral, and VAC Saponin — produced through its proprietary Q-SAP extraction and purification platform. The company's products are sold to human vaccine developers, veterinary vaccine manufacturers, and global health organizations as raw adjuvant material for incorporation into commercial and clinical-stage vaccines.
Differentiator
Problem solved
Functional benefit
Brands
- QS-21 XP (INFINITY): Next-generation saponin-based adjuvant with over 95% pure QS-21 molecules, designed to support innovation in vaccine development.
- QS-21 GH
- QS-Oral
- VAC Saponin
- Q-SAP
Products and services
- QS-21 XP (INFINITY)
- QS-21 GH (Global Health)
- QS-Oral
- VAC Saponin
Quantifiable outcome
- Production capacity increased by 1,000x compared to traditional bark extraction methods
- +4 more outcomes
Companies that use Q-VANT Biosciences
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles4 records
Q-VANT Biosciences technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Q-VANT Biosciences partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Tulane UniversitycoreQ-VANT collaborates with Tulane University to develop a novel oral vaccine adjuvant combining Tulane's dmLT adjuvant with Q-VANT's QS-Oral saponin adjuvant into a synergistic delivery approach called SDA. The NIH awarded Tulane up to $9.2 million over five years for this program. The project focuses on developing needle-free oral vaccines against polio and diarrheal diseases, with Q-VANT providing its sustainably sourced Quillaja-based saponins and formulation expertise.
- SPI PharmacoreSPI Pharma and Q-VANT entered a strategic partnership including investment to expand Q-VANT's Q-SAP technology and an exclusive commercial agreement to accelerate global adoption of high-purity saponin adjuvants for veterinary and human vaccine formulations. SPI Pharma leverages its global pharmaceutical reach, regulatory expertise, logistics, and customer support to serve as the exclusive commercial channel for Q-VANT's products including QS-21 GH, QS-21 INFINITY, and VAC Saponin.
- In Vitro Plant-tech ABcoreQ-VANT signed an agreement with In Vitro Plant-tech AB, a Swedish plant cell cultivation company, to develop and supply Quillaja saponaria plant cell culture biomass. This collaboration creates an additional source of raw materials for Q-VANT, adding flexibility of worldwide production and complementing the company's high-density plantations and greenhouses.
- PATHcorePATH, a global health nonprofit, collaborates with Q-VANT and Tulane University to support the development of oral vaccine formulations for the NIH-funded program. PATH works on methods to combine SDA formulations into pill or dissolvable tablet forms for global health applications.
- Henry Jackson Foundation Inc. and Navy Medical Research CommandminorAdditional partnership alongside Tulane collaboration enabling testing of the oral vaccine platform against major bacterial causes of diarrheal disease in children, soldiers, and travelers by targeting Enterotoxigenic E. coli and Campylobacter.
- Rapid Response Partnership Vehicle (RRPV)minorQ-VANT is a member of the Rapid Response Partnership Vehicle (RRPV), a consortium focused on preparedness for rapid vaccine development responses to emerging pandemic threats.
- BioMap Consortium (Biopharmaceutical Manufacturing Preparedness)minorQ-VANT is a member of the BioMap Consortium, a biopharmaceutical manufacturing preparedness consortium focused on strengthening manufacturing capabilities for future health emergencies.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Q-VANT Biosciences competitors and assessment
Company assessmentDirect peers
- Agenus: Agenus developed the Stimulon saponin adjuvant platform (including QS-21) for use in its own and partnered vaccines. Directly competes with Q-VANT in the saponin adjuvant space serving immuno-oncology and infectious disease vaccines.
- Desert King Chile: Traditional supplier of Quillaja saponaria extracts and saponin adjuvants from bark. Q-VANT's predecessor supplier and direct competitor for the same raw material and adjuvant customer base.
- Croda International (Brenntag Biosector): Croda acquired Brenntag Biosector, the historical dominant supplier of saponin-based adjuvants including QS-21 to GSK and other vaccine developers. Directly comparable as a saponin adjuvant manufacturer serving the same vaccine customer base.
- Phibro Animal Health: Animal health company with a vaccine and adjuvant portfolio across livestock and aquaculture. Directly comparable to Q-VANT's veterinary saponin adjuvant business (VAC Saponin) targeting the same vet vaccine manufacturers.
- In Vitro Plant-tech AB: Swedish plant cell culture company partnering with Q-VANT to supply Quillaja saponaria biomass. Operates in the same saponin supply chain with a competing/complementary raw material source.
Broad incumbents
- Novavax: Novavax's Matrix-M adjuvant is a saponin-based formulation that uses Quillaja saponins, making it both a customer/competitor for saponin supply and a developer of competing vaccine adjuvant technology.
- Seppic (Air Liquid Healthcare): Seppic is a leading manufacturer of vaccine adjuvants (e.g., Montanide, squalene-based) serving the same global vaccine developer customers. Overlaps with Q-VANT in adjuvant supply but spans a wider portfolio of adjuvant chemistries.
Emerging players
- VBI Vaccines: Vaccine developer that has incorporated saponin adjuvants into its pipeline and represents the type of downstream customer Q-VANT serves, with partial overlap in adjuvant strategy.
- EuBiologics: Korean biopharmaceutical company developing saponin-based adjuvants (Quil-A derivatives) for human and veterinary vaccines. Early-stage competitor with overlapping product profile to QS-21 INFINITY.
Others
- SPI Pharma: Exclusive global commercial channel partner for Q-VANT's saponin adjuvants and a strategic investor. Adjacent rather than competitive—operates as the distribution and regulatory services layer for Q-VANT's products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Q-VANT Biosciences social profiles
Digital presenceQ-VANT Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Q-VANT Biosciences leadership team
Management profileNumber of profiles
Profiles4 records
Q-VANT Biosciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Q-VANT Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Q-VANT Biosciences
What does Q-VANT Biosciences do?
Q-VANT Biosciences manufactures and supplies saponin-based vaccine adjuvants — including QS-21 XP (INFINITY), QS-21 GH (Global Health), QS-Oral, and VAC Saponin — produced through its proprietary Q-SAP extraction and purification platform. The company's products are sold to human vaccine developers, veterinary vaccine manufacturers, and global health organizations as raw adjuvant material for incorporation into commercial and clinical-stage vaccines.
Is Q-VANT Biosciences a public or private company?
Q-VANT Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Q-VANT Biosciences founded?
Q-VANT Biosciences was founded in 2022. It employs 11 to 50 people.
Where is Q-VANT Biosciences based?
Q-VANT Biosciences is headquartered in Forestdale (Boston area), United States, in the North America region.
How does Q-VANT Biosciences make money?
Two revenue lines are on record. Saponin Adjuvant Product Sales are the primary driver. The others are licensing and Supply Agreements.
Who are Q-VANT Biosciences's main competitors?
Direct peers on record are Agenus, Desert King Chile, Croda International (Brenntag Biosector), Phibro Animal Health and In Vitro Plant-tech AB. Broad incumbents are Novavax and Seppic (Air Liquid Healthcare). Emerging players are VBI Vaccines and EuBiologics. SPI Pharma is listed as an others.
Does Q-VANT Biosciences have an API?
No public API is recorded for Q-VANT Biosciences.
What industry is Q-VANT Biosciences in?
Q-VANT Biosciences's product category is Vaccine Adjuvants. Its primary akta.pro industry code is HLAIAEAI, Vaccine Adjuvants & Formulation Systems, with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.